{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:12:37Z","timestamp":1792696357257,"version":"4.5.0"},"reference-count":111,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes &amp; Metabolism"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.diabet.2021.101285","type":"journal-article","created":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T15:17:23Z","timestamp":1632842243000},"page":"101285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["The diuretic effects of SGLT2 inhibitors: A comprehensive review of their specificities and their role in renal protection"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1480-5761","authenticated-orcid":false,"given":"Pierre","family":"Delanaye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9743-4371","authenticated-orcid":false,"given":"Andre J.","family":"Scheen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2021.101285_bib0001","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41574-020-0392-2","article-title":"Sodium-glucose co-transporter type 2 inhibitors for the treatment of type 2 diabetes mellitus","volume":"16","author":"Scheen","year":"2020","journal-title":"Nature Rev Endocrinol"},{"key":"10.1016\/j.diabet.2021.101285_bib0002","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41581-021-00393-8","article-title":"Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors","volume":"17","author":"DeFronzo","year":"2021","journal-title":"Nature Rev Nephrol"},{"key":"10.1016\/j.diabet.2021.101285_bib0003","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.2337\/dc21-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2021.101285_bib0004","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1002\/ehf2.13169","article-title":"Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis","volume":"7","author":"Butler","year":"2020","journal-title":"ESC Heart Failure"},{"key":"10.1016\/j.diabet.2021.101285_bib0005","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","article-title":"Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus","volume":"75","author":"Scheen","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.diabet.2021.101285_bib0006","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2021.101285_bib0007","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2021.101285_bib0008","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2021.101285_bib0009","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2021.101285_bib0010","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2021.101285_bib0011","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfab096","article-title":"SGLT2 inhibitors: renal outcomes according to baseline albuminuria","author":"Delanaye","year":"2021","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.diabet.2021.101285_bib0012","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2021.101285_bib0013","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdiacomp.2015.10.012","article-title":"EMPA-REG - the \"diuretic hypothesis\"","volume":"30","author":"McMurray","year":"2016","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.diabet.2021.101285_bib0014","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1253\/circj.CJ-16-0780","article-title":"Diuretic action of sodium-glucose cotransporter 2 inhibitors and its importance in the management of heart failure","volume":"80","author":"Kimura","year":"2016","journal-title":"Circ J"},{"key":"10.1016\/j.diabet.2021.101285_bib0015","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1161\/CIRCULATIONAHA.120.048057","article-title":"Sodium-glucose cotransporter-2 Inhibitors and loop diuretics for heart failure: priming the natriuretic and metabolic reserve of the kidney","volume":"142","author":"Grodin","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2021.101285_bib0016","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.cmet.2021.02.016","article-title":"A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors","volume":"33","author":"Sen","year":"2021","journal-title":"Cell Metab"},{"key":"10.1016\/j.diabet.2021.101285_bib0017","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/j.ajkd.2020.08.003","article-title":"SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation","volume":"77","author":"Tuttle","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.diabet.2021.101285_bib0018","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.diabet.2016.05.006","article-title":"Reappraisal of the diuretic effect of empagliflozin in EMPA-REG OUTCOME: comparison with classic diuretics","volume":"42","author":"Scheen","year":"2016","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2021.101285_bib0019","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20030629","article-title":"Diuretic effects of sodium glucose cotransporter 2 inhibitors and their influence on the renin-angiotensin system","volume":"20","author":"Ansary","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.diabet.2021.101285_bib0020","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2021.101285_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2015.07.072","article-title":"Diuretic effects of sodium-glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and heart failure","volume":"201","author":"Takeuchi","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.diabet.2021.101285_bib0022","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40360-017-0125-x","article-title":"Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes","volume":"18","author":"Kawasoe","year":"2017","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.diabet.2021.101285_bib0023","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/dom.12486","article-title":"Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension","volume":"17","author":"Amin","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2021.101285_bib0024","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/nep.13552","article-title":"Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: a comparison study with furosemide and tolvaptan","volume":"24","author":"Ohara","year":"2019","journal-title":"Nephrology"},{"key":"10.1016\/j.diabet.2021.101285_bib0025","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/ejhf.1713","article-title":"Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)","volume":"22","author":"Damman","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.diabet.2021.101285_bib0026","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.clinthera.2014.02.022","article-title":"Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants","volume":"36","author":"Devineni","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.diabet.2021.101285_bib0027","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.2337\/dc09-0517","article-title":"A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment","volume":"32","author":"Wilding","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2021.101285_bib0028","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ejhf.2066","article-title":"Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure","volume":"23","author":"Boorsma","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.diabet.2021.101285_bib0029","doi-asserted-by":"crossref","first-page":"440","DOI":"10.2337\/dc20-2604","article-title":"Natriuretic effect of two weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of the DAPASALT trial","volume":"44","author":"Scholtes","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2021.101285_bib0030","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s12325-015-0200-x","article-title":"Pharmacokinetics, pharmacodynamics, and safety of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a randomized, single-blind, placebo-controlled trial","volume":"32","author":"Sasaki","year":"2015","journal-title":"Adv Ther"},{"key":"10.1016\/j.diabet.2021.101285_bib0031","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/dom.12322","article-title":"Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus","volume":"16","author":"Sha","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2021.101285_bib0032","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s12325-015-0234-0","article-title":"Pharmacokinetics, pharmacodynamics, and safety of canagliflozin in Japanese patients with type 2 diabetes mellitus","volume":"32","author":"Iijima","year":"2015","journal-title":"Adv Ther"},{"key":"10.1016\/j.diabet.2021.101285_bib0033","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s12325-016-0457-8","article-title":"Factors affecting canagliflozin-induced transient urine volume increase in patients with type 2 diabetes mellitus","volume":"34","author":"Tanaka","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.diabet.2021.101285_bib0034","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s13300-018-0385-5","article-title":"Empagliflozin induces transient diuresis without changing long-term overall fluid balance in Japanese patients with type 2 diabetes","volume":"9","author":"Yasui","year":"2018","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.diabet.2021.101285_bib0035","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","article-title":"Empagliflozin in heart failure: diuretic and cardiorenal effects","volume":"142","author":"Griffin","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2021.101285_bib0036","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3390\/jcm8060779","article-title":"Effects of dapagliflozin on volume status when added to renin-angiotensin system inhibitors","volume":"8","author":"Eickhoff","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.diabet.2021.101285_bib0037","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","article-title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial","volume":"97","author":"van Bommel","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.diabet.2021.101285_bib0038","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/clpt.2008.250","article-title":"Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus","volume":"85","author":"Komoroski","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.diabet.2021.101285_bib0039","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.2215\/CJN.09630818","article-title":"Clinical pharmacology in diuretic use","volume":"14","author":"Ellison","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.diabet.2021.101285_bib0040","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1161\/CIRCULATIONAHA.120.048739","article-title":"Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure: the RECEDE-CHF trial","volume":"142","author":"Mordi","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2021.101285_bib0041","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1007\/s00380-020-01597-x","article-title":"Mechanisms and prediction of short-term natriuretic effect of sodium-glucose cotransporter 2 inhibitor in heart failure patients coexisting type 2 diabetes mellitus","volume":"35","author":"Fukuoka","year":"2020","journal-title":"Heart Vessels"},{"key":"10.1016\/j.diabet.2021.101285_bib0042","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10741-020-10038-w","article-title":"SGLT2-inhibitors; more than just glycosuria and diuresis","volume":"26","author":"Fathi","year":"2021","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.diabet.2021.101285_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.cardfail.2021.07.003","article-title":"The potential roles of osmotic and nonosmotic sodium handling in mediating the effects of sodium-glucose cotransporter 2 inhibitors on heart failure","author":"Bjornstad","year":"2021","journal-title":"J Card Fail"},{"key":"10.1016\/j.diabet.2021.101285_bib0044","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2021.101285_bib0045","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1111\/dom.13855","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes","volume":"21","author":"Dekkers","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2021.101285_bib0046","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S2213-8587(20)30382-X","article-title":"Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial","volume":"9","author":"Jensen","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2021.101285_bib0047","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1111\/dom.14352","article-title":"Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: results from the DEFINE-HF trial","volume":"23","author":"Nassif","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2021.101285_bib0048","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/dom.13126","article-title":"Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis","volume":"20","author":"Hallow","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2021.101285_bib0049","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ejhf.2086","article-title":"Empagliflozin and renal sodium handling: an intriguing smart osmotic diuretic","volume":"23","author":"Mullens","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.diabet.2021.101285_bib0050","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12933-019-0852-y","article-title":"Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy","volume":"18","author":"Schork","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabet.2021.101285_bib0051","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13098-020-00545-z","article-title":"The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease","volume":"12","author":"Ohara","year":"2020","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.diabet.2021.101285_bib0052","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1093\/eurheartj\/ehaa183","article-title":"Effects of dapagliflozin in DAPA-HF according to background heart failure therapy","volume":"41","author":"Docherty","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabet.2021.101285_bib0053","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.120.050391","article-title":"Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF","volume":"143","author":"Jhund","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2021.101285_bib0054","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1507\/endocrj.EJ18-0022","article-title":"Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION)","volume":"65","author":"Nomiyama","year":"2018","journal-title":"Endocr J"},{"key":"10.1016\/j.diabet.2021.101285_bib0055","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2337\/dc08-1863","article-title":"Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes","volume":"32","author":"List","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2021.101285_bib0056","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","article-title":"Effect of empagliflozin on erythropoietin levels, iron stores and red blood cell morphology in patients with type 2 diabetes and coronary artery disease","volume":"141","author":"Mazer","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2021.101285_bib0057","first-page":"105","article-title":"Dapagliflozin suppresses hepcidin and increases erythropoiesis","author":"Ghanim","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2021.101285_bib0058","doi-asserted-by":"crossref","first-page":"844","DOI":"10.14740\/jocmr2760w","article-title":"Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys","volume":"8","author":"Sano","year":"2016","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.diabet.2021.101285_bib0059","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1111\/obr.12755","article-title":"Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms","volume":"19","author":"Lee","year":"2018","journal-title":"Obes Rev"},{"key":"10.1016\/j.diabet.2021.101285_bib0060","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2021.101285_bib0061","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11892-018-0976-6","article-title":"Type 2 diabetes and thiazide diuretics","volume":"18","author":"Scheen","year":"2018","journal-title":"Curr. Diab. Rep."},{"key":"10.1016\/j.diabet.2021.101285_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.jash.2014.01.007","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis","volume":"8","author":"Baker","year":"2014","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.diabet.2021.101285_bib0063","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11906-019-0920-4","article-title":"Blood pressure lowering and sodium-glucose co-transporter 2 inhibitors (SGLT2is): more than osmotic diuresis","volume":"21","author":"Sternlicht","year":"2019","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.diabet.2021.101285_bib0064","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1258\/acb.2011.011281","article-title":"Diuretics: a review","volume":"49","author":"Wile","year":"2012","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.diabet.2021.101285_bib0065","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cmet.2020.06.014","article-title":"SGLT2 inhibitor: not a traditional diuretic for heart failure","volume":"32","author":"Verma","year":"2020","journal-title":"Cell Metab"},{"key":"10.1016\/j.diabet.2021.101285_bib0066","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11886-019-1165-1","article-title":"Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure","volume":"21","author":"Scheen","year":"2019","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.diabet.2021.101285_bib0067","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jacbts.2019.11.007","article-title":"SGLT2 inhibitor-induced sympathoinhibition: a novel mechanism for cardiorenal protection","volume":"5","author":"Herat","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.diabet.2021.101285_bib0068","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-020-01127-z","article-title":"Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial","volume":"19","author":"Shimizu","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabet.2021.101285_bib0069","doi-asserted-by":"crossref","first-page":"7684","DOI":"10.3390\/ijms22147684","article-title":"Sympatholytic mechanisms for the beneficial cardiovascular effects of SGLT2 inhibitors: a research hypothesis for dapagliflozin's effects in the adrenal gland","volume":"22","author":"Lymperopoulos","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.diabet.2021.101285_bib0070","article-title":"Diuretic-induced hypokalaemia: an updated review","author":"Lin","year":"2021","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.diabet.2021.101285_bib0071","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00000441-200001000-00002","article-title":"Diuretic complications","volume":"319","author":"Greenberg","year":"2000","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.diabet.2021.101285_bib0072","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/ckj\/sfaa133","article-title":"Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program","volume":"14","author":"Weir","year":"2021","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.diabet.2021.101285_bib0073","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s13300-015-0150-y","article-title":"Effect of the SGLT2 inhibitor dapagliflozin on potassium levels in patients with type 2 diabetes mellitus: a pooled analysis","volume":"7","author":"Yavin","year":"2016","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.diabet.2021.101285_bib0074","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.2215\/CJN.02130221","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk of abnormal serum potassium level","volume":"16","author":"Hwang","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.diabet.2021.101285_bib0075","first-page":"ehab497","article-title":"Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial","author":"Neuen","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabet.2021.101285_bib0076","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2019.06.007","article-title":"Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: a post hoc analysis of 10 randomized, placebo-controlled trials","volume":"33","author":"Toto","year":"2019","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.diabet.2021.101285_bib0077","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.2337\/dc21-0236","article-title":"Serum magnesium is inversely associated with heart failure, atrial fibrillation, and microvascular complications in type 2 diabetes","volume":"44","author":"Oost","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2021.101285_bib0078","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/dom.14295","article-title":"Diabetogenic effects of cardioprotective drugs","volume":"23","author":"Bell","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2021.101285_bib0079","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.5114\/amsad.2021.105314","article-title":"Empagliflozin therapy and insulin resistance-associated disorders: effects and promises beyond a diabetic state","volume":"6","author":"Papaetis","year":"2021","journal-title":"Arch Med Sci Atheroscler Dis"},{"key":"10.1016\/j.diabet.2021.101285_bib0080","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s11906-020-01116-3","article-title":"Management of hyperuricemia in patients with chronic kidney disease: a focus on renal protection","volume":"22","author":"Kielstein","year":"2020","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.diabet.2021.101285_bib0081","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/dom.13101","article-title":"Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials","volume":"20","author":"Zhao","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2021.101285_bib0082","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1089\/dia.2017.0070","article-title":"Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus","volume":"19","author":"Ahmadieh","year":"2017","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.diabet.2021.101285_bib0083","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1080\/00325481.2016.1153941","article-title":"Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials","volume":"128","author":"Johnsson","year":"2016","journal-title":"Postgrad Med"},{"key":"10.1016\/j.diabet.2021.101285_bib0084","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1186\/s12882-019-1633-2","article-title":"Estimating the risk of acute kidney injury associated with use of diuretics and renin angiotensin aldosterone system inhibitors: a population based cohort study using the clinical practice research datalink","volume":"20","author":"Scott","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.diabet.2021.101285_bib0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002983","article-title":"Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: a systematic review and meta-analysis","volume":"16","author":"Menne","year":"2019","journal-title":"PLoS Med"},{"key":"10.1016\/j.diabet.2021.101285_bib0086","article-title":"Canagliflozin and kidney-related adverse events in type 2 diabetes and CKD: findings from the randomized CREDENCE trial","author":"Heerspink","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.diabet.2021.101285_bib0087","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.kint.2019.02.033","article-title":"Analysis from the EMPA-REG OUTCOME((R)) trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics","volume":"96","author":"Mayer","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.diabet.2021.101285_bib0088","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1053\/j.ajkd.2020.05.014","article-title":"We can finally stop worrying about SGLT2 inhibitors and acute kidney injury","volume":"76","author":"Sridhar","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.diabet.2021.101285_bib0089","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1161\/CIRCULATIONAHA.117.028814","article-title":"Cardiorenal syndrome revisited","volume":"138","author":"Zannad","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2021.101285_bib0090","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.cca.2014.10.041","article-title":"Biomarkers and physiopathology in the cardiorenal syndrome","volume":"443","author":"Bouquegneau","year":"2015","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.diabet.2021.101285_bib0091","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/14656566.2018.1551362","article-title":"Preventing and treating kidney disease in patients with type 2 diabetes","volume":"20","author":"Delanaye","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.diabet.2021.101285_bib0092","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","article-title":"Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials","volume":"7","author":"Heerspink","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2021.101285_bib0093","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/ndt\/13.7.1682","article-title":"The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide","volume":"13","author":"Buter","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.diabet.2021.101285_bib0094","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1681\/ASN.2004060505","article-title":"Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents","volume":"16","author":"Esnault","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.diabet.2021.101285_bib0095","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1159\/000517020","article-title":"The forgotten antiproteinuric properties of diuretics","volume":"52","author":"Trujillo","year":"2021","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.diabet.2021.101285_bib0096","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2021.101285_bib0097","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2021.101285_bib0098","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1097\/HJH.0000000000002050","article-title":"The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Piperidou","year":"2019","journal-title":"J Hypertens"},{"key":"10.1016\/j.diabet.2021.101285_bib0099","doi-asserted-by":"crossref","first-page":"13009","DOI":"10.1038\/s41598-019-49525-y","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on renal outcomes in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"9","author":"Bae","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.diabet.2021.101285_bib0100","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S2213-8587(20)30185-6","article-title":"Reductions in albuminuria with SGLT2 inhibitors: a marker for improved renal outcomes in patients without diabetes?","volume":"8","author":"Sternlicht","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2021.101285_bib0101","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1681\/ASN.2020050723","article-title":"Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: a post hoc analysis from the CREDENCE trial","volume":"31","author":"Oshima","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.diabet.2021.101285_bib0102","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016976","article-title":"Short-term changes in albuminuria and risk of cardiovascular and renal outcomes in type 2 diabetes mellitus: a post hoc analysis of the EMPA-REG OUTCOME trial","volume":"9","author":"Waijer","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.diabet.2021.101285_bib0103","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.jacc.2019.12.059","article-title":"Diuretic therapy for patients with heart failure: JACC state-of-the-art review","volume":"75","author":"Felker","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2021.101285_bib0104","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.2215\/CJN.01120211","article-title":"Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus","volume":"6","author":"Thakar","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.diabet.2021.101285_bib0105","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1136\/heartjnl-2018-314158","article-title":"Change in renal function associated with drug treatment in heart failure: national guidance","volume":"105","author":"Clark","year":"2019","journal-title":"Heart"},{"key":"10.1016\/j.diabet.2021.101285_bib0106","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1159\/000501081","article-title":"A potential mechanism of cardio-renal protection with sodium-glucose cotransporter 2 inhibitors: amelioration of renal congestion","volume":"44","author":"Kuriyama","year":"2019","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.diabet.2021.101285_bib0107","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/ejhf.2220","article-title":"Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial","volume":"23","author":"Pellicori","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.diabet.2021.101285_bib0108","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2112411","article-title":"Empagliflozin and major renal outcomes in heart failure","author":"Packer","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2021.101285_bib0109","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1681\/ASN.2016030278","article-title":"Canagliflozin slows progression of renal function decline independently of glycemic effects","volume":"28","author":"Heerspink","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.diabet.2021.101285_bib0110","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1053\/j.ajkd.2019.03.432","article-title":"Glucose control and the effect of empagliflozin on kidney outcomes in type 2 diabetes: an analysis from the EMPA-REG OUTCOME trial","volume":"74","author":"Cooper","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.diabet.2021.101285_bib0111","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.diabet.2016.12.010","article-title":"Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: focus on SGLT2 inhibitors and EMPA-REG OUTCOME","volume":"43","author":"Scheen","year":"2017","journal-title":"Diabetes Metab"}],"container-title":["Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363621000689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363621000689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:59:00Z","timestamp":1761130740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363621000689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":111,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S1262363621000689"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2021.101285","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The diuretic effects of SGLT2 inhibitors: A comprehensive review of their specificities and their role in renal protection","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2021.101285","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101285"}}